A detailed history of Schonfeld Strategic Advisors LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 186,440 shares of NTLA stock, worth $3.93 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
186,440
Previous 25,721 624.86%
Holding current value
$3.93 Million
Previous $707,000 490.1%
% of portfolio
0.03%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $3.22 Million - $4.37 Million
160,719 Added 624.86%
186,440 $4.17 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $612,674 - $843,648
25,721 New
25,721 $707,000
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $1.24 Million - $1.79 Million
-39,118 Reduced 78.11%
10,960 $346,000
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $444,387 - $591,531
12,851 Added 34.52%
50,078 $2.04 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $1.24 Million - $1.67 Million
37,227 New
37,227 $1.39 Million
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $1.24 Million - $1.64 Million
-22,930 Reduced 51.07%
21,970 $1.23 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $808,290 - $1.6 Million
21,000 Added 87.87%
44,900 $2.32 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $1.39 Million - $2.84 Million
23,900 New
23,900 $1.74 Million
Q3 2021

Nov 16, 2021

SELL
$132.37 - $176.78 $661,850 - $883,900
-5,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $304,400 - $809,550
5,000 New
5,000 $810,000
Q1 2021

May 17, 2021

SELL
$46.59 - $83.68 $1.49 Million - $2.67 Million
-31,880 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$18.83 - $63.53 $600,300 - $2.03 Million
31,880 New
31,880 $1.73 Million
Q1 2018

May 15, 2018

SELL
$19.43 - $34.95 $221,968 - $399,268
-11,424 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$17.39 - $31.12 $198,663 - $355,514
11,424
11,424 $220,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.6B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.